secwatch.observer — SEC 8-K summary
======================================

Issuer:     MetaVia Inc. (MTVA)
CIK:        0001638287
Form:       8-K
Filed at:   2025-05-14T23:59:59+00:00
Accession:  0001558370-25-007740
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MetaVia reports Q1 net loss $3.7M; DA-1726 shows 4.3% mean weight loss in Phase 1
--------------------------------------------------------------------------------

- Cash $11.2M at Q1-end; plus $10M private placement in May, funding into 2026.
- Net loss $3.7M ($0.36/sh) vs $6.7M ($1.32/sh) YoY; R&D spend down to $2.3M from $4.9M.
- DA-1726 (obesity) mean weight loss 4.3% at 32 mg at Day 26 (p=0.0005); max 6.3%; no titration needed.
- DA-1241 (MASH) Phase 2a reduced ALT 22.8 U/L at 16 weeks; end-of-Phase 2 FDA meeting expected H1 2025.
- Additional DA-1726 dose cohorts to start Q3 2025; data expected Q4 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/0001558370-25-007740-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1638287/000155837025007740/mtva-20250514x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-007740

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer